Brief: Cadrenal Therapeutics To Submit FDA Rare Pediatric Disease Designation Request For Tecarfarin In Kawasaki Disease
18/06/2026 14:09
BRIEF-Cadrenal Therapeutics To Submit FDA Rare Pediatric Disease Designation Request For Tecarfarin In Kawasaki Disease June 18 (Reuters) - Cadrenal Therapeutics Inc CVKD.O:
CADRENAL THERAPEUTICS - TO SUBMIT FDA RARE PEDIATRIC DISEASE DESIGNATION REQUEST FOR TECARFARIN IN KAWASAKI DISEASE
Source text: ID:nGNX97r0zd
Further company coverage: CVKD.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Cadrenal Therapeutics
See all newsCadrenal Therapeutics Inc reports results for the quarter ended June 30 - Earnings Summary
Cadrenal Therapeutics Q2 net loss narrows as operating expenses fall
Cadrenal Therapeutics Inc expected to post a loss of $1.42 a share - Earnings Preview
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Salesforce
U.S. STOCKS ON THE MOVE-SpaceX, Sandisk, Marvell Technology